Glenmark Pharma receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate foam
The drug is the generic version of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS
Glenmark Pharma has been granted tentative approval by the US Food and Drug Administration (FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic version of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS.
According to IQVIA sales data for the 12-month period ending March 2022, the Enstilar Foam 0.005% |0.064% market achieved annual sales of approximately $115.2 million.
- Advertisement -